Protara is committed to advancing transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead program, TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational, intravenous phospholipid substrate replacement therapy in development for the treatment of intestinal failure-associated liver disease. For more information, visit www.protaratx.com.
Looking for a particular Protara Therapeutics employee's phone or email?
Protara Therapeutics Questions
The Protara Therapeutics annual revenue was $10.1 million in 2026.
Jesse Shefferman is the CEO of Protara Therapeutics.
40 people are employed at Protara Therapeutics.
Protara Therapeutics is based in New York, New York.
The NAICS codes for Protara Therapeutics are [325, 54, 541, 32, 3254].
The SIC codes for Protara Therapeutics are [28, 283, 80].
Top Protara Therapeutics Employees
-
Jesse Shefferman
Chief Executive Officer at Protara Therapeutics
New York, NY, US35+ -
Patrick Fabbio
Chief Financial Officer at Protara Therapeutics
New York, NY, US35+ -
Jacqueline Zummo
Co-founder and Chief Scientific Operations Officer at Protara Therapeutics
New York, United States45+ -
Shane Williams
Chief People Officer at Protara Therapeutics
New York, NY, US21 -
35+
-
Bill Conkling
Chief Commercial Officer (CCO) at Protara Therapeutics
New York, NY, US24 -
Hannah F
VP, Controller at Protara Therapeutics
New York, NY, US1 -
21
-
25+
